Emricasan

Overview

Emricasan (PF 03491390) is an orally active and irreversible pan-caspase inhibitor. Emricasan inhibits Zika virus (ZIKV) -induced increases in caspase-3 activity and protected human cortical neural progenitors.

Application

Products | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Flavivirus

Product Information

• Catalog No.: HY-10396
• CAS No.: 254750-02-2
• Molecular Formula: C26H27F4N3O7
• Molecular Weight: 569.50
• Purity: 99.81%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (4.39 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source